Actavia Life Sciences, Inc. (RASP)

0.0169 +0.0025 (+17.36%) At close: 12:29PM EDT

Actavia Life Sciences, Inc.

5 Penn Plaza
19th Floor #1954
New York, NY 10001
United States
646 396 4087
https://www.rasna.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 1

Key executives

Name	Title	Pay	Exercised	Year born
Ms. Keeren Shah	Chief Financial Officer	15k	N/A	1976
Mr. Willy Jules Simon	Executive Chairman	N/A	N/A	1951

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Actavia Life Sciences, Inc., a leukemia-focused biotechnology company, engages in developing therapeutics for the treatment of acute myeloid leukemia (AML) and other forms of leukemia and lymphoma. It is developing RASP-201, a novel, orally dosed, selective reversible inhibitor of lysine specific demethylase, a pathway that blocks differentiation and confers a poor prognosis to AML; and RASP-301, an NCE for NPM1, currently at the pre-clinical stage to treat refractory AML with reduced toxicity. The company was formerly known as Rasna Therapeutics, Inc. and changed its name to Actavia Life Sciences, Inc. in October 2023. Actavia Life Sciences, Inc. was founded in 2013 and is headquartered in New York, New York.

Corporate governance

Actavia Life Sciences, Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.